LED Medical Diagnostics Inc. (“LED Medical”, “the Company”), a developer of tissue visualization detection technologies for the medical industry, said today that its market-leading VELscope® Vx Enhanced Oral Assessment System can play an important role in helping clinicians discover oral abnormalities beyond oral cancer and pre-cancer.
“While our VELscope® Vx is best-known for being the world’s number one adjunctive device for the detection of oral cancer and pre-cancer, it also helps clinicians detect a wide range of other types of non-cancerous abnormalities,” said Peter Whitehead, founder and CEO of LED Medical Diagnostics and its LED Dental subsidiary, which manufactures the VELscope® Vx. Other types of oral abnormalities detected by the VELscope® Vx include:
- Viral, fungal and bacterial infections
- Inflammation from a variety of causes (including lichen planus and lichenoid reactions)
- Squamous papillomas
- Salivary gland tumors
“While not all of these abnormalities are necessarily life-threatening, the exception being many types of salivary gland tumors, they can be a source of significant pain, discomfort and ill health,” said Mr. Whitehead. “These are conditions that patients need and want to have detected, and they understand that a dental practice that can discover and treat these conditions is providing exceptional care for its patients.”
Mr. Whitehead also pointed out that a misperception sometimes results when a lesion detected by the VELscope® Vx is biopsy-confirmed to be a non-cancerous form of oral disease. “Some people who don’t use the VELscope® Vx somehow interpret this as a ‘false positive’ result because the condition isn’t related to cancer,” he said. “The fact of the matter is that the VELscope® Vx is an oral disease discovery device, not an oral cancer diagnostic device.” He added, “Our job is to help clinicians detect any oral mucosal abnormality that could be cause for concern, and we do that job extremely well. The job of diagnosing those abnormalities falls to the clinician, who generally uses some combination of his or her clinical judgment, oral cytology and surgical biopsy. And, whether the ultimate diagnosis is cancer or non-cancer, the patient is dramatically better off for having received it.” Mr. Whitehead also stressed that surgical biopsy is the only definitive form of diagnosis for oral lesions.
According to Mr. Whitehead, clinicians already using the VELscope® Vx fully understand its importance in detecting non-cancerous types of oral disease. A survey found that VELscope® Vx users give the device virtually identically high marks for its abilities to detect cancerous and non-cancerous lesions. He added, “In fact, users also indicate that the vast majority of the lesions they detect with the VELscope® Vx are non-cancerous, and that they are extremely satisfied with the impact the device has had on their practice.”